Allison Dorval - 29 Nov 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Financial Officer
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Allison Dorval
Issuer symbol
VERV
Transactions as of
29 Nov 2021
Transactions value $
$0
Form type
4
Filing time
30 Nov 2021, 15:26:58 UTC
Previous filing
16 Jul 2021
Next filing
15 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +135,000 $0.000000 135,000 29 Nov 2021 Common Stock 135,000 $33.25 Direct F1
transaction VERV Restricted Stock Units Award $0 +7,500 $0.000000 7,500 29 Nov 2021 Common Stock 7,500 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on November 29, 2021. 25% of the shares underlying the option will vest on November 29, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until November 29, 2025.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On November 29, 2021, the reporting person was granted 7,500 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.